Physician profile
Abbas Rabiei
NPI 1447242268
$11,661.68
in general payments reported to CMS, 2019-2025
42 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $445 · 2021: $1,251 · 2022: $2,079 · 2023: $1,915 · 2024: $2,679 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,914 · Education: $7.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,914.34 |
| Education | $7.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,896.57 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Bayer Healthcare Pharmaceuticals INC. | $1,395.27 | 2021-2025 | |
| Amgen INC. | $923.21 | 2019-2025 | Tavneos, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $847.91 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $562.07 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $545.80 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $533.27 | 2021-2024 | Terlivaz, Acthar |
| Novo Nordisk INC | $484.60 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $345.26 | 2019-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $334.80 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $313.63 | 2019-2025 | Rayaldee |
| Lilly USA, LLC | $283.23 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $277.18 | 2019-2024 | Amplatzer Talisman |
| Travere Therapeutics, INC. | $264.41 | 2023-2025 | Filspari |
| Ardelyx, INC. | $256.96 | 2024-2025 | Ibsrela |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Rabiei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.